S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
Log in
NASDAQ:AVRO

AVROBIO Stock Forecast, Price & News

$14.59
+0.55 (+3.92 %)
(As of 01/22/2021 04:30 PM ET)
Add
Compare
Today's Range
$13.55
Now: $14.59▼
$14.64
50-Day Range
$12.82
MA: $14.30▼
$15.75
52-Week Range
$9.76
Now: $14.59▼
$29.32
Volume335,682 shs
Average Volume291,556 shs
Market Capitalization$531.82 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41
AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company has a research and clinical collaboration agreement with Magenta Therapeutics to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
AVROBIO logo

MarketRank™

Overall MarketRank™

1.67 out of 5 stars

Medical Sector

251st out of 1,922 stocks

Biological Products, Except Diagnostic Industry

30th out of 177 stocks

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AVRO
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.avrobio.com
Phone617-914-8420
Employees123

Debt

Debt-to-Equity RatioN/A
Current Ratio9.14
Quick Ratio9.14

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5.87 per share
Price / Book2.49

Profitability

EPS (Most Recent Fiscal Year)($2.66)
Net Income$-72,960,000.00
Net MarginsN/A
Return on Equity-51.33%
Return on Assets-47.65%

Miscellaneous

Outstanding Shares36,451,000
Market Cap$531.82 million
Next Earnings Date3/15/2021 (Estimated)
OptionableNot Optionable
$14.59
+0.55 (+3.92 %)
(As of 01/22/2021 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVRO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AVROBIO (NASDAQ:AVRO) Frequently Asked Questions

How has AVROBIO's stock price been impacted by Coronavirus (COVID-19)?

AVROBIO's stock was trading at $18.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AVRO stock has decreased by 19.0% and is now trading at $14.59.
View which stocks have been most impacted by COVID-19.

Is AVROBIO a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AVROBIO stock.
View analyst ratings for AVROBIO or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than AVROBIO?

Wall Street analysts have given AVROBIO a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AVROBIO wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as AVROBIO's CEO?

1,448 employees have rated AVROBIO CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among AVROBIO's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is AVROBIO's next earnings date?

AVROBIO is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for AVROBIO.

How were AVROBIO's earnings last quarter?

AVROBIO, Inc. (NASDAQ:AVRO) released its quarterly earnings results on Tuesday, November, 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.81) by $0.20.
View AVROBIO's earnings history.

What price target have analysts set for AVRO?

7 brokers have issued 12-month target prices for AVROBIO's shares. Their forecasts range from $13.00 to $43.00. On average, they anticipate AVROBIO's stock price to reach $32.17 in the next twelve months. This suggests a possible upside of 120.5% from the stock's current price.
View analysts' price targets for AVROBIO or view Wall Street analyst' top-rated stocks.

Who are some of AVROBIO's key competitors?

Some companies that are related to AVROBIO include Replimune Group (REPL), NantKwest (NK), Vericel (VCEL), Scholar Rock (SRRK), Translate Bio (TBIO), BioCryst Pharmaceuticals (BCRX), REGENXBIO (RGNX), C4 Therapeutics (CCCC), Forma Therapeutics (FMTX), Atara Biotherapeutics (ATRA), Krystal Biotech (KRYS), Cellectis (CLLS), Inhibrx (INBX), Adverum Biotechnologies (ADVM) and Aligos Therapeutics (ALGS).
View all of AVRO's competitors.

What other stocks do shareholders of AVROBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVROBIO investors own include Sorrento Therapeutics (SRNE), ImmunoGen (imgn), Aduro Biotech (ADRO), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Biohaven Pharmaceutical (BHVN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), VBI Vaccines (vbiv) and Arbutus Biopharma (ABUS).

Who are AVROBIO's key executives?

AVROBIO's management team includes the following people:
  • Mr. Geoff MacKay, Co- Founder, Pres, CEO & Director (Age 54, Pay $746.7k)
  • Mr. Erik Ostrowski, CFO & Treasurer (Age 47, Pay $739.58k)
  • Mr. Steven N. Avruch J.D., Chief Legal Officer & Sec. (Age 59, Pay $441.68k)
  • Mr. Jeffrey Medin Ph.D., Scientific Founder
  • Mr. Matthew Arnold, Head of Operations
  • Mr. Kim Raineri M.B.A., Chief Manufacturing & Technology Officer
  • Mr. Chris Mason, Chief Scientific Officer
  • Ms. Monique Da Silva, Sr. VP of Corp. Communications
  • Ms. Georgette Verdin, Chief HR Officer
  • Ms. Deanna M. Petersen, Chief Bus. Officer (Age 58)

When did AVROBIO IPO?

(AVRO) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.

What is AVROBIO's stock symbol?

AVROBIO trades on the NASDAQ under the ticker symbol "AVRO."

How do I buy shares of AVROBIO?

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AVROBIO's stock price today?

One share of AVRO stock can currently be purchased for approximately $14.59.

How big of a company is AVROBIO?

AVROBIO has a market capitalization of $531.82 million. The company earns $-72,960,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. AVROBIO employs 123 workers across the globe.

What is AVROBIO's official website?

The official website for AVROBIO is www.avrobio.com.

How can I contact AVROBIO?

AVROBIO's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.